Shares of Tata Motors ended higher by over 0.5 per cent Rs 409.50 after gaining over 3 per cent earlier in the day.

Led by monthly sales volume data, shares of the company climbed 3.57 per cent to Rs 421.85 on the BSE.

On the NSE, it rose 3.5 per cent to Rs 422 as the company reported a 9.9 per cent growth in sales at 39,763 units in April against 36,190 units during the same month last year.

The company had announced the monthly sales volume data after market hours yesterday.

Domestic sales of Tata Motors’ commercial and passenger vehicles rose 11 per cent to 35,978 units during the month from 32,404 units in April 2015.

Sales of passenger vehicles in the domestic market stood at 11,161 units last month against 10,341 a year ago, up 7.9 per cent, Tata Motors said in a statement.

In the commercial vehicles segment, the company’s domestic sales came in at 25,138 units, up 13.3 per cent over April 2015.

Hero MotoCorp

Shares of two-wheeler maker Hero MotoCorp ended down by 0.68 per cent at Rs 2,888 after gaining nearly 2 per cent earlier in the day.

Buoyed by 14.89 per cent increase in sales last month, the stock earlier climbed 1.76 per cent to Rs 2,959 on the BSE. On the NSE, it went up by 1.91 per cent to Rs 2,960.05.

The company’s sales number came post market hours yesterday.

The country’s largest two-wheeler maker Hero MotoCorp had yesterday reported 14.89 per cent increase in sales at 6,12,739 units in April.

The company had sold 5,33,305 units in April 2015, Hero MotoCorp had said in a statement.

Having grown by 13.6 per cent and 14 per cent in February and March, respectively, this is a third straight month of double-digit growth for Hero MotoCorp, the statement added.

HDFC

Shares of HDFC ended the session up by 0.62 per cent at Rs 1,099.50.

Encouraged by a jump of nearly 31 per cent in consolidated net profit for the March quarter, the stock earlier gained 2.12 per cent to Rs 1,116 on the BSE. On the NSE, shares of the company rose 2.25 per cent to Rs 1,116.55.

Home finance major HDFC had yesterday reported a nearly 31 per cent jump in consolidated net profit at Rs 3,460.5 crore for the March quarter, boosted by the sale of part stake in its life insurance arm for Rs 1,513 crore.

The company’s net profit after taxes was Rs 2,646.35 crore in January-March quarter of 2014-15.

In March, the company had sold 9 per cent of its stake in HDFC Life to Standard Life Mauritius Holdings for a total consideration of Rs 1,706 crore, which yielded a net income of Rs 1,513 crore, HDFC Vice-Chairman and Chief Executive Keki Mistry said.

On a standalone basis, the net income rose 40 per cent to Rs 2,607 crore from Rs 1,862 crore driven by the one-time income.

For the full fiscal, the consolidated net profit rose 16.3 per cent to Rs 10,190.3 crore from Rs 8,762.6 crore after providing Rs 3,015 crore for tax, including Rs 379 crore as deferred tax liability on special reserves.

Aurobindo shares surge

Shares of Aurobindo Pharma gained on USFDA approval for epilepsy drug.

The stock gained as much as 5.1 per cent, highest since February 1, on US FDA approval for its epilepsy prevention drug lacosamide.

It ended the session higher by 4.19 per cent at Rs 801.95.

Credit Suisse has initiated stock coverage with “outperform’’ rating, and given a price target of Rs 950.

According to Thomson Reuters data, the stock’s median price target is Rs 941.50.

The brokerage says Aurobindo is a beneficiary of faster approvals in the US. All key plants of the company are FDA compliant.

Credit Suisse says US accounts for 80 per cent of Aurobindo’s profits, it expects strong US sales CAGR of 20 per cent over next two years.

Related Topics
comment COMMENT NOW